New treatment for autoimmune diseases may benefit millions of people

In a recent study, researchers have developed a series of molecules that may provide more reliable relief with fewer side effects for people with autoimmune diseases.

The study was conducted by Purdue University.

The new molecules overcome difficulties with current drugs in targeting, for purposes of inhibiting, the appropriate form of Janus kinase, which has four forms affecting cell signaling and gene expression.

Living with an autoimmune disease can feel like an insider is attacking your body.

It is estimated 24 million people in the United States are affected by autoimmune diseases, a group of diseases in which the person’s immune system attacks part of the person’s own body.

The new inhibitors discovered by the study may provide relief for people suffering from rheumatoid arthritis, psoriasis, myelofibrosis and other autoimmune diseases with a reduction in side effects compared with current therapies.

The compounds contribute a new structural chemotype that is expected to have unique pharmacological properties relative to the other known Janus kinase inhibitors.

The team said the new molecules also show potential to allow for more treatment options for people with autoimmune diseases.

Abnormalities of the immune system often lead to autoimmune diseases or cancer.

The researchers have filed a patent with the Purdue Office of Technology Commercialization and the technology is available for licensing.

Professor Mark Cushman leads the research team.

The research appears in the Journal of Medicinal Chemistry.

Copyright © 2019 Knowridge Science Report. All rights reserved.

Source: Journal of Medicinal Chemistry.